| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (replaced TA222) |
|
Medicine details |
|
| Medicine name | trabectedin (Yondelis®) |
| Formulation | powder for concentrate for solution for infusion |
| Reference number | 319 |
| Indication | In combination with pegylated liposomal doxorubicin (PLD) for the treatment of patients with relapsed platinum-sensitive ovarian cancer |
| Company | Pharma Mar SA |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/12/2009 |
| NICE guidance | |